Current News

Contact | Print version | PDF version | Send article | RSS feed

ProtAffin AG strengthens Scientific Advisory Board

12 Jun 2008 - ProtAffin AG announced that it has strengthened its Scientific Advisory Board with the appointment of Dr. Antal Rot.
 
Dr. Rot is currently Group Head at the Novartis Institute of Biomedical Research (NIBR) in Vienna, Austria and is a key figure in the field of chemokine biology and the role of chemokines in inflammatory diseases. He has published many seminal papers, including articles on the interaction between chemokines and cell-surface glycan structures. Dr. Rot initially trained as a medical doctor and Pathologist, and carried out post-doctoral research at the National Institutes of Health (NIH) in the US. He has worked at the NIBR in Vienna for the last 20 years.
 
Professor Andreas Kungl, CSO of ProtAffin, commented: "I am delighted that we have been able to attract Dr. Rot to ProtAffin's Scientific Advisory Board. He is a renowned and respected leader in the field of chemokine involvement in inflammation and we will benefit greatly from his leading expertise as we bring our chemokine-based lead product PA401 into clinical development."